Irbesartan Hydrochlorothiazide Accord-Uk

Irbesartan, the active ingredient in Irbesartan Hydrochlorothiazide Accord-Uk, is an Angiotensin II receptor blocker presented as a combination tablet for oral use. Together with hydrochlorothiazide, a thiazide diuretic, it helps lower blood pressure by reducing vascular resistance and plasma volume in adult patients with hypertension who need additional control.

GNH USA supplies Irbesartan Hydrochlorothiazide Accord-Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent product quality, regulatory adherence and reliable logistics for global healthcare providers.

Irbesartan/Hydrochlorothiazide is used to manage hypertension, a condition characterized by elevated arterial pressure.

- Hypertension: lowers systolic and diastolic blood pressure in patients requiring combined ARB and diuretic therapy. - Hypertension with fluid retention: reduces plasma volume and improves blood pressure control in patients with edema. - Hypertension in diabetic patients: assists in blood pressure management and may help reduce proteinuria associated with diabetic nephropathy.

Common Side Effects: - Dizziness: feeling light‑headed or unsteady. - Headache: mild to moderate pain in the head region. - Increased urination: more frequent need to void. - Electrolyte imbalance: especially low potassium levels. - Fatigue: general feeling of tiredness. - Mild gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Acute kidney injury: sudden decrease in kidney function. - Hyperkalemia: dangerously high potassium levels. - Severe hypotension: marked drop in blood pressure causing faintness.

Patients should be monitored regularly while taking this medication. - Blood pressure monitoring: ensure therapeutic targets are achieved without excessive lowering. - Renal function assessment: check serum creatinine and eGFR periodically. - Electrolyte surveillance: especially potassium and sodium levels. - Pregnancy avoidance: drug is contraindicated in pregnancy due to fetal risk. - Elderly caution: start at lower doses and monitor for orthostatic effects. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid): - Aliskiren: combined renin‑angiotensin blockade can increase risk of renal impairment. - Potassium‑sparing diuretics (e.g., spironolactone): may cause hyperkalemia. - Lithium: increased lithium levels and toxicity risk. - NSAIDs (high dose): can reduce antihypertensive effect and worsen kidney function.

Moderate Interactions (Monitor Closely): - ACE inhibitors: additive blood pressure lowering; monitor for hypotension. - Other antihypertensives: may enhance hypotensive effect. - CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan plasma concentrations.